Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.November 10, 2023 at 5:06 AM · 3 min read. With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX) may be sending very bearish signals at the moment, given ...The firm has a market cap of $2.09 billion, a PE ratio of -6.60 and a beta of 0.63. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report) last announced its earnings results on Thursday ...114% vs Avg 9.70 Day Range 10.68 4.54 52 Week Range 16.75 Partner Center Your Watchlists Customize MarketWatch Have Watchlists? Log in to see them here or sign …SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ...Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings. That means RXRX is a top biotech stock capturing the overall trend rather than betting the farm on a single drug or therapeutic. And major players are taking note. Nvidia (NASDAQ: NVDA) is betting ...Jan 17, 2024 · Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media. Current. Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance.6 days ago · PTC Therapeutics (NASDAQ:PTCT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better investment?We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Biotech firm Recursion (NASDAQ:RXRX) said on Wednesday that it had secured a $50M investment from Nvidia , which was implemented as a private investment in public equity. RXRX shares jump +72.7% ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.May 29, 2023 · On May 8, Recursion Pharmaceuticals (RXRX-2.63%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... Dec 14, 2023 · Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that is involved in decoding biology and screening drugs to arrange them in a way that can aid the efficient ...Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …The stock price for . Recursion Pharmaceuticals (NASDAQ: RXRX) is $9.98 last updated Today at January 18, 2024 at 7:59 PM EST. Q Does Recursion …Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals (NASDAQ:RXRX), expressing a variety of opinions spanning from bullish to bearish.SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to …So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a $1.7bn biopharma company which uses the Recursion OS, or Operating System, methods that it claims makes the drug discovery process more efficient.Recursion Pharmaceuticals Inc Insider Sells Shares. Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Insider Monkey.Recursion Pharmaceuticals (RXRX-1.25%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...Jul 13, 2023 · Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing.This ... 1 day ago · The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last year, but it's still early innings for ... Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ...Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 320.7% in the third quarter, according to the company in its most recent ...Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year.Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) last month posted second-quarter results. GAAP EPS in the quarter came in at -$0.38. Revenue in the period jumped 42.9% year over year to $11 million.Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...Nov 16, 2023 · JuSun/iStock via Getty Images. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline.That's because it has been advancing two ... AMD. Advanced Micro Devices, Inc. Common Stock. $177.25 -3.08 -1.71%. Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share ... Recursion Pharmaceuticals ( RXRX -2.00%) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...Jan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …PTC Therapeutics (NASDAQ:PTCT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better investment?We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, …Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...The budgetary allocation to AI and machine learning in healthcare is expected to reach 10.5% in 2024, up from 5.5% in 2022, Morgan Stanley says. Read more here.After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.27%) on July 12, Recursion Pharmaceuticals ( RXRX 8.83%) saw its stock blast off, rising 87% over the following two ...Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago.Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX) climbed on Thursday after the AI-led biotech announced a licensing agreement with German conglomerate Bayer ( OTCPK:BAYZF) to in-license a new ...Jan 19, 2024 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ... Nasdaq GS (USD) As of 12: ... 2023-09-11 09:35:31 ET. Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative.Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 320.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The institutional investor owned 3,523,124 shares of the company's stock …4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist Add to Portfolio RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS …Fintel reports that on April 18, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation. Analyst Price Forecast Suggests 173.84% UpsideReal time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Fintel reports that on April 18, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation. Analyst Price Forecast Suggests 173.84% UpsideRecursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Jul 13, 2023 · Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ... It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals ( RXRX 4.83%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... Jul 14, 2023 · Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ... The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on January 17, 2024.The analyst firm set a price target for $15.00 expecting RXRX to rise to within ... Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd …In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share …Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Welcome to Recursion: The Future of TechBio. LEARN HOW ›. NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. Shares of NASDAQ:RXRX opened at $10.23 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The firm’s 50 day moving average is $9.27 and its two ...SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,GuruFocus Research January 25, 2024 at 8:52 PM · 2 min read Director Blake Borgeson of Recursion Pharmaceuticals Inc ( NASDAQ:RXRX) has sold 20,054 shares …Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …Dec 19, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) made waves this year as the AI-centric biotech company got a $50 million investment from mega-firm Nvidia (NASDAQ: NVDA). The enthusiasm proved short-lived ... Jan 12, 2024 · imagedepotpro. Investment Overview. The last time I covered Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) for Seeking Alpha was back in May last year, when I gave the company's stock a "hold ... Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, …Shares of Recursion Pharmaceuticals (RXRX-2.63%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.December 9, 2023 at 11:06 AM · 4 min read. In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023. This ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States.Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Recursion Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View RXRX financial statements in full.Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.Nasdaq rxrx, converse x scooby doo shoe collab release what you need to.htm, camaro v6 0 60
Over the past 3 months, she has purchased 1,900,644 RXRX shares via her ARKG ETF, and her overall holdings now stands at 6,192,719 shares. ... The Nasdaq Composite still hasn't recouped all of its .... Nasdaq rxrx
salary at samRXRX Recursion Pharmaceuticals Inc Form 144 ... Recursion Pharmaceuticals (NASDAQ:RXRX) Historical Stock Chart From Dec 2023 to Jan 2024 Recursion Pharmaceuticals (NASDAQ: ...Jan 17, 2024 · Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals (NASDAQ:RXRX), expressing a variety of opinions spanning from bullish to bearish. A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to …Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Get the latest ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed …Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the newer innovative biotech stocks to buy. Having gone public in April 2021, the company claims it is working to reinvent drug discovery. They ...Find the latest on option chains for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the newer innovative biotech stocks to buy. Having gone public in April 2021, the company claims it is working to reinvent drug discovery. They ...RXRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Recursion Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and …3. Big pharma appears to be in the mood to collaborate. The last green flag for biotech stocks is that big pharma players like Pfizer are actively searching for businesses to collaborate with in ...RXRX Recursion Pharmaceuticals Inc Form 144 ... Recursion Pharmaceuticals (NASDAQ:RXRX) Historical Stock Chart From Dec 2023 to Jan 2024 Recursion Pharmaceuticals (NASDAQ: ...3. Its services segment has yet to prove its value. Recursion has three segments: Its pipeline, discovery collaborations, and software licensing. Its pipeline projects are still early-stage, so ...N/A Dividend Yield N/A Price Target $11.20 Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Jul 6, 2023 · Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ... Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-3.13%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... May 8, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ... 4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ... Jan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ... Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Price, Quote, News & History | Nasdaq Created with Sketch. Market Activity Funds + ETFs P/E & PEG Ratios when trading, helping... Recursion Pharmaceuticals Inc Insider Sells Shares. Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Insider Monkey.AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the newer innovative biotech stocks to buy. Having gone public in April 2021, the company claims it is working to reinvent drug discovery. They ...Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. 3. Its services segment has yet to prove its value. Recursion has three segments: Its pipeline, discovery collaborations, and software licensing. Its pipeline projects are still early-stage, so ...Dec 16, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) has built one of the world’s most advanced AI-powered platforms to help decode human biology. RXRX gathers data and experiments on millions of biological ... The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...For a biotech like Recursion Pharmaceuticals (RXRX-1.25%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ...Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ...Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...May 8, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ... Nasdaq Futures 17,538.50 +100.00(+0.57%) Russell 2000 Futures 1,961.90 +7.10(+0.36%) Crude Oil 73.13 -0.28(-0.38%) Gold 2,023.30 -6.00(-0.30%) Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS -... In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings. Dec 22, 2023 · The NASDAQ 100 After Hours Indicator is down -8.22 to 16,769.18. The total After hours volume is currently 64,637,594 shares traded.The following are the most active stocks for the after hours ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ...The budgetary allocation to AI and machine learning in healthcare is expected to reach 10.5% in 2024, up from 5.5% in 2022, Morgan Stanley says. Read more here.Welcome to Recursion: The Future of TechBio. LEARN HOW ›. NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ...Recursion Pharmaceuticals (RXRX-1.25%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...AMD. Advanced Micro Devices, Inc. Common Stock. $177.25 -3.08 -1.71%. Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share ... Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …2023-09-11 09:35:31 ET. Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative.3. Big pharma appears to be in the mood to collaborate. The last green flag for biotech stocks is that big pharma players like Pfizer are actively searching for businesses to collaborate with in ...Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day. Now trading above that level — and up in five of the last six ...Dec 14, 2023 · Clinical-stage biotech companies often take time to be profitable. Recursion's total revenue in Q3 dipped to $10.5 million compared to $13.2 million in Q3 2022. Its net loss in the quarter came in ... It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the newer innovative biotech stocks to buy. Having gone public in April 2021, the company claims it is working to reinvent drug discovery. They ...Recursion Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View RXRX financial statements in full.Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 320.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The institutional investor owned 3,523,124 shares of the company's stock …. Mide, enorme bite noire